These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7566518)

  • 1. Effect of previous antidepressant therapy on the growth hormone response to apomorphine.
    Pitchot W; Hansenne M; Gonzalez Moreno A; Ansseau M
    Neuropsychobiology; 1995; 32(1):19-22. PubMed ID: 7566518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone response to apomorphine in panic disorder: comparison with major depression and normal controls.
    Pichot W; Hansenne M; Gonzalez Moreno A; Ansseau M
    Eur Arch Psychiatry Clin Neurosci; 1995; 245(6):306-8. PubMed ID: 8527467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The biological basis of suicidal behavior: neuroendocrine and psychophysiological approach to the role of catecholamines].
    Pitchot W; Hansenne M; Gonzalez Moreno A; Wauthy J; Ansseau M
    Acta Psychiatr Belg; 1995; 95(4-5):210-33. PubMed ID: 8525861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth hormone response to apomorphine in obsessive-compulsive disorder.
    Pitchot W; Hansenne M; Moreno AG; Ansseau M
    J Psychiatry Neurosci; 1996 Nov; 21(5):343-5. PubMed ID: 8973055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tricyclic wash-out and growth hormone response to clonidine.
    Schittecatte M; Charles G; Machowski R; Wilmotte J
    Br J Psychiatry; 1989 Jun; 154():858-63. PubMed ID: 2597894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suicidal behavior and growth hormone response to apomorphine test.
    Pitchot W; Hansenne M; Moreno AG; Ansseau M
    Biol Psychiatry; 1992 Jun; 31(12):1213-9. PubMed ID: 1391282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychopathological correlates of dopaminergic disturbances in major depression.
    Pitchot W; Hansenne M; Moreno AG; von Frenckell R; Ansseau M
    Neuropsychobiology; 1990-1991; 24(4):169-72. PubMed ID: 2135707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blunted response of growth hormone to clonidine and apomorphine in endogenous depression.
    Ansseau M; Von Frenckell R; Cerfontaine JL; Papart P; Franck G; Timsit-Berthier M; Geenen V; Legros JJ
    Br J Psychiatry; 1988 Jul; 153():65-71. PubMed ID: 3224252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced dopaminergic activity in depressed suicides.
    Pitchot W; Reggers J; Pinto E; Hansenne M; Fuchs S; Pirard S; Ansseau M
    Psychoneuroendocrinology; 2001 Apr; 26(3):331-5. PubMed ID: 11166495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic sensitivity and prediction of antidepressant response.
    Healy E; McKeon P
    J Psychopharmacol; 2000 Jun; 14(2):152-6. PubMed ID: 10890309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noradrenergic and dopaminergic interrelation in schizophrenia.
    Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
    Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced dopamine function in depressed patients is related to suicidal behavior but not its lethality.
    Pitchot W; Hansenne M; Gonzalez Moreno A; Pinto E; Reggers J; Fuchs S; Pirard S; Ansseau M
    Psychoneuroendocrinology; 2001 Oct; 26(7):689-96. PubMed ID: 11500250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth-hormone response to clonidine in panic disorder patients in comparison to patients with major depression and healthy controls.
    Gann H; Riemann D; Stoll S; Berger M; Müller WE
    Pharmacopsychiatry; 1995 May; 28(3):80-3. PubMed ID: 7568369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroendocrine evaluation of catecholaminergic neurotransmission in mania.
    Ansseau M; von Frenckell R; Cerfontaine JL; Papart P; Franck G; Timsit-Berthier M; Geenen V; Legros JJ
    Psychiatry Res; 1987 Nov; 22(3):193-206. PubMed ID: 2829258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic function in panic disorder: comparison with major and minor depression.
    Pitchot W; Ansseau M; Gonzalez Moreno A; Hansenne M; von Frenckell R
    Biol Psychiatry; 1992 Dec; 32(11):1004-11. PubMed ID: 1467380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noradrenergic dysfunction and antidepressant treatment response.
    Corrêa H; Duval F; Claude MM; Bailey P; Tremeau F; Diep TS; Crocq MA; Castro JO; Macher JP
    Eur Neuropsychopharmacol; 2001 Apr; 11(2):163-8. PubMed ID: 11313162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.
    Zemlan FP; Hirschowitz J; Garver DL
    Arch Gen Psychiatry; 1986 Dec; 43(12):1162-7. PubMed ID: 3778112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dopamine in non-depressed patients with a history of suicide attempts.
    Pitchot W; Hansenne M; Ansseau M
    Eur Psychiatry; 2001 Nov; 16(7):424-7. PubMed ID: 11728856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the growth hormone responses to clonidine and apomorphine in the same patients with endogenous depression.
    Corn TH; Hale AS; Thompson C; Bridges PK; Checkley SA
    Br J Psychiatry; 1984 Jun; 144():636-9. PubMed ID: 6743929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.